BR102012028120B8 - Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento - Google Patents

Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento

Info

Publication number
BR102012028120B8
BR102012028120B8 BR102012028120A BR102012028120A BR102012028120B8 BR 102012028120 B8 BR102012028120 B8 BR 102012028120B8 BR 102012028120 A BR102012028120 A BR 102012028120A BR 102012028120 A BR102012028120 A BR 102012028120A BR 102012028120 B8 BR102012028120 B8 BR 102012028120B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
drug
ingenol
ingenol derivatives
derivatives
Prior art date
Application number
BR102012028120A
Other languages
English (en)
Other versions
BR102012028120A2 (pt
BR102012028120B1 (pt
Inventor
Ferreira Telles Everardo
Francisco Pianowski Luiz
Original Assignee
Amazonia Fitomedicamentos Ltda
Fund Pio Xii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50626235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR102012028120(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amazonia Fitomedicamentos Ltda, Fund Pio Xii filed Critical Amazonia Fitomedicamentos Ltda
Priority to BR102012028120A priority Critical patent/BR102012028120B8/pt
Priority to JP2015538216A priority patent/JP2016502509A/ja
Priority to KR1020157010257A priority patent/KR20150073997A/ko
Priority to CN201380057344.XA priority patent/CN104755455B/zh
Priority to US14/439,927 priority patent/US20150315124A1/en
Priority to ES13850517.7T priority patent/ES2668921T3/es
Priority to EP13850517.7A priority patent/EP2915800B1/en
Priority to CA2889944A priority patent/CA2889944C/en
Priority to PT138505177T priority patent/PT2915800T/pt
Priority to MX2015005525A priority patent/MX2015005525A/es
Priority to PCT/BR2013/000455 priority patent/WO2014066967A1/pt
Priority to AU2013337538A priority patent/AU2013337538B2/en
Priority to NZ707636A priority patent/NZ707636A/en
Priority to RU2015114967A priority patent/RU2662712C2/ru
Publication of BR102012028120A2 publication Critical patent/BR102012028120A2/pt
Priority to IL238043A priority patent/IL238043A/en
Priority to ZA2015/03005A priority patent/ZA201503005B/en
Priority to HK15110775.3A priority patent/HK1210136A1/xx
Priority to US15/094,686 priority patent/US9713601B2/en
Publication of BR102012028120B1 publication Critical patent/BR102012028120B1/pt
Publication of BR102012028120B8 publication Critical patent/BR102012028120B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
    • C07C69/618—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety having unsaturation outside the six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/013—Esters of alcohols having the esterified hydroxy group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond

Abstract

COMPOSTO DERIVADO DE INGENOL, COMPOSIÇÃO FARMACÊUTICA, MEDICAMENTO, USO DE UM OU MAIS DERIVADOS DE INGENOL E MÉTODO DE TRATAMENTO A presente invenção refere-se a novos compostos derivados de ingenol para o tratamento de câncer. Em outros aspectos a invenção refere-se a composição farmacêutica, medicamento e método de tratamento de câncer.
BR102012028120A 2012-11-01 2012-11-01 Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento BR102012028120B8 (pt)

Priority Applications (18)

Application Number Priority Date Filing Date Title
BR102012028120A BR102012028120B8 (pt) 2012-11-01 2012-11-01 Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
RU2015114967A RU2662712C2 (ru) 2012-11-01 2013-10-31 Производные ингенола, применяемые для лечения рака
PT138505177T PT2915800T (pt) 2012-11-01 2013-10-31 Compostos derivados de ingenol que podem ser utilizados para tratamento do cancro
PCT/BR2013/000455 WO2014066967A1 (pt) 2012-11-01 2013-10-31 Compostos derivados de ingenol úteis no tratamento de câncer
CN201380057344.XA CN104755455B (zh) 2012-11-01 2013-10-31 可用于治疗癌症的巨大戟醇衍生化合物
US14/439,927 US20150315124A1 (en) 2012-11-01 2013-10-31 Ingenol-derived compounds that can be used for treating cancer
ES13850517.7T ES2668921T3 (es) 2012-11-01 2013-10-31 Compuestos derivados de ingenol que pueden usarse para tratar cáncer
EP13850517.7A EP2915800B1 (en) 2012-11-01 2013-10-31 Ingenol-derived compounds that can be used for treating cancer
CA2889944A CA2889944C (en) 2012-11-01 2013-10-31 Ingenol derivative compounds useful for treating cancer
JP2015538216A JP2016502509A (ja) 2012-11-01 2013-10-31 がんを治療するのに有効なインゲノール誘導化合物
MX2015005525A MX2015005525A (es) 2012-11-01 2013-10-31 Compuestos derivados de ingenol utiles para trata de cancer.
KR1020157010257A KR20150073997A (ko) 2012-11-01 2013-10-31 암을 치료하기 위해 이용될 수 있는 인게놀-유도 화합물
AU2013337538A AU2013337538B2 (en) 2012-11-01 2013-10-31 Ingenol-derived compounds that can be used for treating cancer
NZ707636A NZ707636A (en) 2012-11-01 2013-10-31 Ingenol-derived compounds that can be used for treating cancer
IL238043A IL238043A (en) 2012-11-01 2015-03-30 Ingrenol-derived compounds for cancer treatment
ZA2015/03005A ZA201503005B (en) 2012-11-01 2015-04-30 Ingenol-derived compounds useful for treating cancer
HK15110775.3A HK1210136A1 (en) 2012-11-01 2015-11-02 Ingenol-derived compounds that can be used for treating cancer
US15/094,686 US9713601B2 (en) 2012-11-01 2016-04-08 Ingenol derivative compounds and methods useful for inhibiting cancer cell viability and treating cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102012028120A BR102012028120B8 (pt) 2012-11-01 2012-11-01 Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento

Publications (3)

Publication Number Publication Date
BR102012028120A2 BR102012028120A2 (pt) 2014-12-02
BR102012028120B1 BR102012028120B1 (pt) 2021-03-09
BR102012028120B8 true BR102012028120B8 (pt) 2022-08-02

Family

ID=50626235

Family Applications (1)

Application Number Title Priority Date Filing Date
BR102012028120A BR102012028120B8 (pt) 2012-11-01 2012-11-01 Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento

Country Status (17)

Country Link
US (2) US20150315124A1 (pt)
EP (1) EP2915800B1 (pt)
JP (1) JP2016502509A (pt)
KR (1) KR20150073997A (pt)
CN (1) CN104755455B (pt)
AU (1) AU2013337538B2 (pt)
BR (1) BR102012028120B8 (pt)
CA (1) CA2889944C (pt)
ES (1) ES2668921T3 (pt)
HK (1) HK1210136A1 (pt)
IL (1) IL238043A (pt)
MX (1) MX2015005525A (pt)
NZ (1) NZ707636A (pt)
PT (1) PT2915800T (pt)
RU (1) RU2662712C2 (pt)
WO (1) WO2014066967A1 (pt)
ZA (1) ZA201503005B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016191836A1 (pt) * 2015-06-03 2016-12-08 Amazônia Fitomedicamentos Ltda. Método de preparação de ingenol-3-dodecanoato, método de preparação de 3-etinil-3-hidroxi-4.7.7-trimetilbiciclo[4.1.0]heptano-2-carbaldeído e método de preparação de 2,2-dimetil-4-etinil-5-trifenilfosforanilideno-1,3-dioxano
WO2016191837A1 (pt) * 2015-06-03 2016-12-08 Amazônia Fitomedicamentos Ltda. Método de preparação de ingenol-3-hexanoato, método de preparação de 3-etinil-3-hidroxi-4.7.7-trimetilbiciclo[4.1.0]heptano-2-carbaldeído e método de preparação do composto 2,2-dimetil-4-etinil-5-trifenilfosforanilideno-1,3-dioxano
WO2017089300A1 (en) * 2015-11-27 2017-06-01 Leo Laboratories Limited 3-alkylamido-3-deoxy-ingenols
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
US11715111B2 (en) 2018-09-25 2023-08-01 Capital One Services, Llc Machine learning-driven servicing interface

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08245505A (ja) * 1994-09-09 1996-09-24 Tosoh Corp ジテルペン誘導体、その製造法及びそれを有効成分として含有する抗腫瘍剤
WO2006007676A1 (en) * 2004-07-21 2006-01-26 Amazônia Fitomedicamentos Ltda. Combination of active fractions from the plants euphorbia tirucalli l and ficos carica l. and method of treating cancer and aids
WO2006116897A1 (fr) * 2005-04-30 2006-11-09 Nihon University Diterpenes provenant de euphorbia kansui et leur utilisation
US20090142421A1 (en) * 2005-06-28 2009-06-04 Amazonia Fitomedicamentos Ltda. Active fraction of a polar solvent extract from the latex of euphorbiaceae plants
CN101257912A (zh) * 2005-06-28 2008-09-03 阿马佐尼亚菲托药品有限公司 大戟科植物乳汁的极性溶剂提取物的活性级份
JP2014507396A (ja) * 2010-12-22 2014-03-27 レオ・ラボラトリーズ・リミテッド イノゲノール−３−アシラートｉ
CA2822310A1 (en) * 2010-12-22 2012-06-28 Gunnar Grue-Sorensen Ingenol-3-acylates iii and ingenol-3-carbamates
NZ628408A (en) * 2012-03-02 2017-09-29 Amazônia Fitomedicamentos Ltda Ingenol derivatives in reactivation of latent hiv virus

Also Published As

Publication number Publication date
MX2015005525A (es) 2015-07-21
EP2915800A4 (en) 2016-04-27
EP2915800A1 (en) 2015-09-09
CA2889944C (en) 2018-09-04
US20160287544A1 (en) 2016-10-06
CA2889944A1 (en) 2014-05-08
PT2915800T (pt) 2018-05-09
WO2014066967A1 (pt) 2014-05-08
BR102012028120A2 (pt) 2014-12-02
RU2662712C2 (ru) 2018-07-27
US20150315124A1 (en) 2015-11-05
CN104755455B (zh) 2018-02-23
CN104755455A (zh) 2015-07-01
AU2013337538A1 (en) 2015-05-21
ZA201503005B (en) 2017-08-30
AU2013337538B2 (en) 2018-03-15
US9713601B2 (en) 2017-07-25
JP2016502509A (ja) 2016-01-28
IL238043A (en) 2017-11-30
HK1210136A1 (en) 2016-04-15
EP2915800B1 (en) 2018-02-28
ES2668921T3 (es) 2018-05-23
BR102012028120B1 (pt) 2021-03-09
NZ707636A (en) 2019-01-25
KR20150073997A (ko) 2015-07-01
RU2015114967A (ru) 2016-12-20

Similar Documents

Publication Publication Date Title
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
BR112015008487A2 (pt) compostos de benzeno substituído
BR112015008447A2 (pt) métodos para tratar câncer
BR112015008365A2 (pt) composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112016000561B8 (pt) Compostos terapeuticamente ativos, uso dos mesmos, composição farmacêutica e uso da mesma
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112015009168A2 (pt) composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4
GEP201706624B (en) Triazolopyrazine as brd4 inhibitors and usage thereof for cancer treatment
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
BR112014008294A2 (pt) anticorpo anti c-met e usos do mesmo
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
EA201491427A1 (ru) Замещенные фенилимидазопиразолы и их применение
BR112018008076A2 (pt) derivados de lapachona contendo dois centros redox e métodos de uso dos mesmos
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
BR112018007673A2 (pt) ?análogos de epotilona, métodos de síntese, métodos de tratamento e conjugados de fármaco dos mesmos?

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/11/2012, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: FUNDACAO PIO XII (BR/SP)

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.007032/2023-10 ORIGEM: 5009703-09.2022.4.03.6100 PROCESSO NO: 5009703-09.2022.4.03.6100 SUB JUDICE AUTOR: LUIZ FRANCISCO PIANOWSKI E KYOLAB LABORATORIO LTDA REU(S): AMAZONIA FITOMEDICAMENTOS LTDA, EVERARDO FERREIRA TELLES, AGROPAULO AGROINDUSTRIAL S/A E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI